Ligand Licenses Injectable Formulation of Topiramate to Start-Up CURx
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 8 (Table of Contents)
Published: 21 Aug-2013
DOI: 10.3833/pdr.v2013.i8.1973 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Ligand Pharmaceuticals has licensed global rights to its Captisol-enabled® topiramate injection to start-up CURx Pharmaceuticals for the treatment of partial onset or primary generalised tonic-clonic seizures in hospitalised epilepsy patients who are unable to take oral topiramate...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS